Short Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Decreases By 24.4%

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a large decline in short interest in July. As of July 31st, there was short interest totaling 1,210,000 shares, adeclineof24.4% from the July 15th total of 1,600,000 shares. Currently,2.1% of the company’s stock are short sold. Based on an average trading volume of 227,300 shares, the days-to-cover ratio is currently 5.3 days. Based on an average trading volume of 227,300 shares, the days-to-cover ratio is currently 5.3 days. Currently,2.1% of the company’s stock are short sold.

Context Therapeutics Trading Up 1.5%

NASDAQ CNTX opened at $0.8930 on Friday. Context Therapeutics has a twelve month low of $0.49 and a twelve month high of $2.62. The company has a market capitalization of $80.10 million, a PE ratio of -2.48 and a beta of 1.89. The business’s 50-day moving average price is $0.72 and its 200 day moving average price is $0.75.

Context Therapeutics (NASDAQ:CNTX) last posted its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). Equities analysts predict that Context Therapeutics will post -0.51 EPS for the current year.

Insider Buying and Selling at Context Therapeutics

In related news, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the business’s stock in a transaction dated Friday, June 6th. The shares were purchased at an average cost of $0.64 per share, with a total value of $25,606.40. Following the completion of the purchase, the chief financial officer owned 80,010 shares in the company, valued at approximately $51,206.40. The trade was a 100.03% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martin A. Lehr acquired 100,000 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The shares were acquired at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the completion of the transaction, the chief executive officer directly owned 920,190 shares of the company’s stock, valued at $644,133. The trade was a 12.19% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired 160,010 shares of company stock worth $107,206 over the last three months. Corporate insiders own 2.80% of the company’s stock.

Institutional Trading of Context Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new stake in Context Therapeutics in the fourth quarter valued at $29,000. Citadel Advisors LLC acquired a new position in Context Therapeutics in the 4th quarter valued at $31,000. Shay Capital LLC acquired a new position in shares of Context Therapeutics during the fourth quarter valued at about $52,000. Walleye Capital LLC grew its position in Context Therapeutics by 51.7% in the fourth quarter. Walleye Capital LLC now owns 166,306 shares of the company’s stock valued at $175,000 after acquiring an additional 56,651 shares during the period. Finally, Millennium Management LLC increased its holdings in shares of Context Therapeutics by 24.2% in the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock valued at $188,000 after purchasing an additional 34,835 shares in the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, August 7th. William Blair reaffirmed an “outperform” rating on shares of Context Therapeutics in a report on Tuesday, April 29th. HC Wainwright reduced their target price on Context Therapeutics from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a research report on Thursday, June 26th. One investment analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $5.25.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.